Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

The Same But Different: Biden Budget Proposes Flexibility For Generic Drug-Device Combos, ‘Skinny Labels’

Executive Summary

President Biden's fiscal year 2024 budget pushes new legislative changes to get generic drugs to market faster. 

You may also be interested in...



US FDA’s Califf Responds To, And Deflects, Senators’ Mifepristone Questions

The Senate Appropriations Subcommittee hearing was called to discuss the agency’s FY 2024 budget request, but several committee members wanted to talk about the pending Supreme Court decision on the medication abortion drug.

Ban On US FDA User Fee Spending For Certain Facility Costs Forced Budget Shift

Soon-to-be enacted limitation on user fees means building maintenance and other expenses must be paid with non-user fee dollars. The issue was thought to be a significant operational impediment, but the most recent appropriations bill provided some relief.

CDER Laments Lack Of Shortage Funding, But FDA Didn’t Request New Money For 2024

CDER head is worried FDA won’t be able to sustain gains the agency made on drug shortages and supply chain work as big CARES Act boost set to run out this year, yet it didn’t ask Congress for new taxpayer funding in the fiscal year 2024 budget request.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS147868

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel